Chest
-
Surgery Case Report Posters IISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Chest wall tumors are rarely seen in the manubrium of the sternum. They are usually metastases, but the most common malignant-primary-tumor is chondrosarcoma. ⋯ The following authors have nothing to disclose: José González García, Sebastian Peñafiel, Eugenia Libreros Niño, Diana Baquero Velandia, Carlos Jordá Aragón, Ángel García ZarzaNo Product/Research Disclosure Information.
-
COPD QVA149 PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Patients with severe-to-very severe COPD require intensified therapy to reduce risk of exacerbations. Such patients may benefit from additional bronchodilation. Once-daily QVA149 is a dual bronchodilator consisting of a fixed-dose combination of two long-acting bronchodilators, indacaterol and glycopyrronium. ⋯ Jadwiga Wedzicha: Consultant fee, speaker bureau, advisory committee, etc.: JW has received speaking fee and/or for advisory boards from GlaxoSmithKline, AstraZeneca, Novartis, Bayer, Boehringer Ingelheim, Nycomed. Chiesi and Respifor as well as travel reimbursements from Boehringer Ingelheim. JW has received research grants from GlaxoSmithKline, AstraZeneca, Chiesi and Novartis. Joachim Ficker: Consultant fee, speaker bureau, advisory committee, etc.: Dr. Ficker has received speaker fees from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Pfizer, Nycomed, Almirall, Berlin-C hemie, Takeda and Novartis, consulting fees from AstraZeneca, Boehringer Ingelheim, and Novartis. Angel FowlerTaylor: Employee: The author is an employee of Novartis Pharmaceuticals Corporation Donald Banerji: Employee: The author is an employee of Novartis Pharmaceuticals Corporation The following authors have nothing to disclose: Dennis Niewohner, Thomas SandströmClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.
-
Congenital Disorder Case Report PostersSESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Common manifestations of Alpha-1 antitrypsin (AAT) deficiency include panacinar emphysema, bronchiectasis, and cirrhosis. Rarely association of inflammatory bowel disease, vasculitis, psoriasis, urticaria, and angioedema have been described. Here, we present an unusual case with necrotizing panniculitis and pulmonary ground glass opacities (GGO) on chest CT. ⋯ Rajiv Dhand: Consultant fee, speaker bureau, advisory committee, etc.: GSK, Grant monies (from industry related sources): International Physician coordinator for astra-zeneca multicenter study; Bayer site PI, GSK site PI, Consultant fee, speaker bureau, advisory committee, etc.: Mylan pharmaceuticals; Cardeas Pharma The following authors have nothing to disclose: Kashif Aslam, Naveed Sheikh, Syed Mudassar Naqshbandi, Amnah AndrabiNo Product/Research Disclosure Information.
-
Surgery Case Report Posters IISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Pancreaticopleural fistulae (PPF) are rare communications between the pancreatic duct and the pleural cavity. More commonly the sequelae of alcoholism, PPF occasional results from peripancreatic surgery. ⋯ The following authors have nothing to disclose: Eric Toloza, Christian Sobky, Anna Cheng, Christy Chai, Ian Smithson, Lori Brown, Carla Moodie, Joseph Garrett, Colin Parsons, Pamela Hodul, Mokenge MalafaNo Product/Research Disclosure Information.
-
Lung Cancer ISESSION TYPE: Slide PresentationsPRESENTED ON: Saturday, March 22, 2014 at 02:15 PM - 03:45 PMPURPOSE: We perform this analysis to improve the understanding of the clinicopathological characteristics and clinical outcome of non-small cell lung cancer (NSCLC) patients harboring EGFR T790M along with activating EGFR mutation. ⋯ The following authors have nothing to disclose: Hang Li, Rui Wang, Haichuan Hu, Yunjian Pan, Lei Wang, Yang Zhang, Yihua Sun, Haiquan ChenNo Product/Research Disclosure Information.